Aceragen Inc is a clinical-stage biopharmaceutical company. The Company is focused on the clinical development, and commercialization, of drug candidates for rare disease indications characterized by small, well-defined patient populations with serious unmet medical needs. The Company’s pipeline includes ACG-701 to treat cystic fibrosis (CF) pulmonary exacerbations (PEx) and melioidosis, and ACG-801 to treat Farber disease.
Its focus is to develop and optimize the commercial value of ACG-701 and ACG-801 for appropriate patients. ACG-701 is an oral, loading dose formulation of sodium fusidate being developed as a potential treatment for PEx associated with cystic fibrosis CF, a factor driving lung function decline in people living with CF.
ACG-701 is also being developed for the treatment of melioidosis, a life-threatening infection that can affect numerous organ systems, including the lungs..
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 5.3K |
| Three Month Average Volume | 1.9M |
| High Low | |
| Fifty-Two Week High | 16 USD |
| Fifty-Two Week Low | 0.3601 USD |
| Fifty-Two Week High Date | 18 Jan 2023 |
| Fifty-Two Week Low Date | 18 Aug 2023 |
| Price and Volume | |
| Current Price | 0.38 USD |
| Beta | 1 |
| Relative Price Change | |
| Four Week Relative Price Change | -49.49% |
| Thirteen Week Relative Price Change | -78.42% |
| Twenty-Six Week Relative Price Change | -91.93% |
| Fifty-Two Week Relative Price Change | -95.99% |
| Year-to-Date Relative Price Change | -94.57% |
| Price Change | |
| One Day Price Change | 0.00% |
| Thirteen Week Price Change | -77.25% |
| Twenty-Six Week Price Change | -91.00% |
| Five Day Price Change | 0.00% |
| Fifty-Two Week Price Change | -95.44% |
| Year-to-Date Price Change | -93.61% |
| Month-to-Date Price Change | 0.00% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 10.65608 USD |
| Book Value Per Share (Most Recent Quarter) | 2.70135 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | -11.97858 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | -5.88011 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -5.25037 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 1.4934 USD |
| Revenue Per Share (Trailing Twelve Months) | 1.68944 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -7.17522 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -8.57145 USD |
| Normalized (Last Fiscal Year) | -5.5223 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -7.17522 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -8.57145 USD |
| Including Extraordinary Items (Last Fiscal Year) | -7.17522 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -8.57145 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 3.29639 USD |
| Cash Per Share (Most Recent Quarter) | 0.25375 USD |
| Cash Flow Per Share (Last Fiscal Year) | -7.17061 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -9.45531 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -6.8617 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -2,573 |
| Cash Flow Revenue (Trailing Twelve Months) | -406 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -649.75% |
| Pretax Margin (Last Fiscal Year) | -610.41% |
| Pretax Margin (5 Year) | -2,304.15% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -572.15% |
| Operating Margin (Trailing Twelve Months) | -603.44% |
| Operating Margin (5 Year) | -2,857.16% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -480.46% |
| Net Profit Margin (Trailing Twelve Months) | -559.86% |
| Net Profit Margin (5 Year) | -2,213.53% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -32.29% |
| Tangible Book Value (5 Year) | -99,999.99% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -99,999.99% |
| Revenue Growth (3 Year) | 40.06% |
| Revenue Change (Trailing Twelve Months) | -99,999.99% |
| Revenue Per Share Growth | 13.89% |
| Revenue Growth (5 Year) | 49.74% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -99,999.99% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | -118.60% |
| EPS Change (Trailing Twelve Months) | -13.72% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | -100,000 |
| Price to Tangible Book (Most Recent Quarter) | -100,000 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -2,118,000 |
| Net Debt (Last Fiscal Year) | -12,044,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 1 |
| Price to Sales (Trailing Twelve Months) | 0 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | 0 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | 0 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 0 |
| Price to Book (Most Recent Quarter) | 0 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 0 |
| Long Term Debt to Equity (Most Recent Quarter) | 0 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 1 |
| Current Ratio (Most Recent Quarter) | 0 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -24,495,000 |
| Free Cash Flow (Trailing Twelve Months) | -29,779,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 0 |
| Total Debt to Equity (Most Recent Quarter) | 0 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -34.36% |
| Return on Assets (Trailing Twelve Months) | -75.58% |
| Return on Assets (5 Year) | -50.18% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -113.18% |
| Return on Equity (Trailing Twelve Months) | -169.66% |
| Return on Equity (5 Year) | -360.78% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -42.59% |
| Return on Investment (Trailing Twelve Months) | -94.40% |
| Return on Investment (5 Year) | -71.33% |